We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+35.24%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.54B
AUM Growth
+$917M
Cap. Flow
+$107M
Cap. Flow %
3.03%
Top 10 Hldgs %
51.42%
Holding
131
New
31
Increased
26
Reduced
8
Closed
26

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$88M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$70.6M
3
BPMC
Blueprint Medicines
BPMC
+$30.6M
4
AMRN
Amarin Corp
AMRN
+$30M
5
TDOC icon
Teladoc Health
TDOC
+$26.6M

Top Sells

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$105M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$71M
3
ARGX icon
argenx
ARGX
+$53.9M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$41M
5
XLRN
Acceleron Pharma
XLRN
+$39.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.08%
2 Miscellaneous 2.54%
3 Consumer Staples 0.8%
4 Financials 0.51%
5 Technology 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGRX
51
DELISTED
Agile Therapeutics
AGRX
$12.7M 0.36%
+4,213
New +$8.93M
MOTS
52
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$12.5M 0.35%
10,702
– –
MTEM
53
DELISTED
Molecular Templates, Inc.
MTEM
$11.5M 0.32%
131,609
– –
PRQR icon
54
ProQR Therapeutics
PRQR
$260M
$10M 0.28%
722,523
– –
ALEC icon
55
Alector
ALEC
$228M
$9.58M 0.27%
+511,731
New +$9.68M
ORTX
56
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$9.33M 0.26%
52,180
– –
HUM icon
57
Humana
HUM
$47.6B
$9.31M 0.26%
+35,000
New +$10.1M
DBVT
58
DBV Technologies
DBVT
$739M
$8.7M 0.25%
112,852
+30,156
+36% +$2.29M
UROV
59
DELISTED
Urovant Sciences Ltd.
UROV
$8.7M 0.25%
865,359
+240,000
+38% +$2.46M
ZYME icon
60
Zymeworks
ZYME
$1.86B
$8.53M 0.24%
573,890
– –
RCKT icon
61
Rocket Pharmaceuticals
RCKT
$374M
$8.04M 0.23%
458,173
+218,000
+91% +$3.44M
SYBX
62
DELISTED
Synlogic
SYBX
$6.59M 0.19%
57,857
– –
ARWR icon
63
Arrowhead Research
ARWR
$9.98B
$6.07M 0.17%
330,738
+30,738
+10% +$507K
SWAV
64
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$5.02M 0.14%
+150,000
New +$4.98M
SRRA
65
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.56M 0.13%
66,655
– –
TBIO
66
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$4.43M 0.13%
435,000
– –
LIVN icon
67
LivaNova
LIVN
$4.38B
$3.89M 0.11%
+40,000
New +$3.73M
RARE icon
68
Ultragenyx Pharmaceutical
RARE
$1.29B
$3.47M 0.1%
+50,000
New +$2.86M
XENT
69
DELISTED
Intersect ENT, Inc
XENT
$2.25M 0.06%
+70,000
New +$2.17M
VERU icon
70
Veru
VERU
$39.9M
$2.08M 0.06%
142,500
– –
EIGR
71
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.96M 0.06%
4,663
– –
ABEOW
72
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$1.91M 0.05%
659,636
– –
GRCE
73
Grace Therapeutics
GRCE
$46.9M
$1.81M 0.05%
37,081
– –
OMED
74
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$1.79M 0.05%
1,719,111
– –
VCRA
75
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$1.58M 0.04%
+50,000
New +$1.77M
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, Perceptive Advisors held 131 positions worth $3.54B, up 35% from $2.63B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors deployed $107M of net new capital in Q1 2019, opening 31 new positions and adding to 26 existing holdings. Its largest new stake was Array Biopharma Inc: 4,228,900 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $71M trimmed.

  • Perceptive Advisors's largest Q1 2019 buy was Array Biopharma Inc: 4,228,900 shares worth $103M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q1 2019, an estimated $70.6M increase.
  • Perceptive Advisors's biggest Q1 2019 reduction was Neurocrine Biosciences, cutting an estimated $71M.
  • Perceptive Advisors fully exited Solid Biosciences in Q1 2019, selling an estimated $105M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $3.54B portfolio in Q1 2019.
  • Perceptive Advisors opened 31 new positions and closed 26 in Q1 2019.
  • Perceptive Advisors's portfolio value rose 35% quarter-over-quarter to $3.54B.

Based on Perceptive Advisors's 13F filing for Q1 2019, filed 15 May 2019.